161 related articles for article (PubMed ID: 33779268)
1. Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy.
Bukhari S; Barakat AF; Eisele YS; Nieves R; Jain S; Saba S; Follansbee WP; Brownell A; Soman P
Circulation; 2021 Mar; 143(13):1335-1337. PubMed ID: 33779268
[No Abstract] [Full Text] [Related]
2. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
[No Abstract] [Full Text] [Related]
3. Atrial Fibrillation, Thromboembolic Risk, and Anticoagulation in Cardiac Amyloidosis: A Review.
Bukhari S; Khan SZ; Bashir Z
J Card Fail; 2023 Jan; 29(1):76-86. PubMed ID: 36122817
[TBL] [Abstract][Full Text] [Related]
4. Wild-type transthyretin cardiac amyloidosis diagnosed in a patient in his 50s.
Tanabe J; Ouchi T; Watanabe N; Tanabe K
BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32606107
[No Abstract] [Full Text] [Related]
5. No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis.
Donnellan E; Elshazly MB; Vakamudi S; Wazni OM; Cohen JA; Kanj M; Hanna M; Baranowski B; Saliba W; Jaber W
JACC Clin Electrophysiol; 2019 Dec; 5(12):1473-1474. PubMed ID: 31857048
[No Abstract] [Full Text] [Related]
6. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.
Longhi S; Quarta CC; Milandri A; Lorenzini M; Gagliardi C; Manuzzi L; Bacchi-Reggiani ML; Leone O; Ferlini A; Russo A; Gallelli I; Rapezzi C
Amyloid; 2015; 22(3):147-55. PubMed ID: 25997105
[TBL] [Abstract][Full Text] [Related]
7. Response: Atrial impairment in transthyretin cardiac amyloidosis: an early marker of cardiac involvement and a prognostic factor.
Henein MY; Lindqvist P
Amyloid; 2018 Jun; 25(2):136. PubMed ID: 29529882
[No Abstract] [Full Text] [Related]
8. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
[No Abstract] [Full Text] [Related]
9. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
[TBL] [Abstract][Full Text] [Related]
10. Management Strategies for Atrial Fibrillation and Flutter in Patients with Transthyretin Cardiac Amyloidosis.
Dale Z; Chandrashekar P; Al-Rashdan L; Kim M; Masri A; Nazer B
Am J Cardiol; 2021 Oct; 157():107-114. PubMed ID: 34366115
[TBL] [Abstract][Full Text] [Related]
11. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
[TBL] [Abstract][Full Text] [Related]
12. Hereditary Transthyretin Amyloid Cardiomyopathy.
Youmans QR; Shah SJ; Khan SS
JAMA Cardiol; 2022 Feb; 7(2):236. PubMed ID: 34935856
[No Abstract] [Full Text] [Related]
13. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
[TBL] [Abstract][Full Text] [Related]
14. Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis.
Henein MY; Suhr OB; Arvidsson S; Pilebro B; Westermark P; Hörnsten R; Lindqvist P
Amyloid; 2018 Mar; 25(1):46-53. PubMed ID: 29369708
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
16. Diffuse Alveolar Septal Amyloidosis With Wild-Type Transthyretin With Spontaneous Lung Hematoma.
Tomita E; Matsuo S; Tsukamoto Y; Fukuhara K; Akashi A
Ann Thorac Surg; 2019 Feb; 107(2):e131-e133. PubMed ID: 30009808
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
18. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL
ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and prognostic implications of orthopedic ligament disorders in patients with wild-type transthyretin amyloidosis cardiomyopathy.
Malik GMA; Samiullah FNU; Khenhrani RR
J Cardiol; 2024 Feb; 83(2):138. PubMed ID: 37783269
[No Abstract] [Full Text] [Related]
20. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease.
Rausch K; Scalia GM; Sato K; Edwards N; Lam AK; Platts DG; Chan J
Int J Cardiovasc Imaging; 2021 Jan; 37(1):81-90. PubMed ID: 32728989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
